OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
07/09/2026
Back to search
Official data from USPTO
ACELLYTRON THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
07/09/2026
Classification
Registered
Trademark type
Combined
Nice classes
5, 35, 42, 44
Filing date
06/03/2024
Registration date
08/19/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/19/2025
Last transaction
07/09/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
CN
Examiner
DIGAN, MATTHEW M
Law office
N60
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the wording "ACELLYTRON THERAPEUTICS" in a blue font with the "O" appearing in a slightly larger font and stylized with the design of a DNA helix and water drop.
Holders and representatives
Holders
Wuxi Biologics (Shanghai) Co., Ltd.
Representatives
Michael T. Smith Birch Stewart Kolasch & Birch, LLP
Technical classification
Nice Classes
Class 5Class 35Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Chemical-pharmaceutical preparations for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; biochemical medicines for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; vaccine preparations; influenza vaccine; chemotherapeutics; stem cells for medical purposes; medicines for human purposes for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; drugs for medical purposesmedicines for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; pharmaceutical preparations for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; drugs for treatment of cancer; medical preparation for treating diseases and disorders related to the immune system; biological agentbiological preparations for treating cancer; pharmaceutical preparations for the prevention and treatment of cancer; living cells for medical use; medical cell inhibitor for inhibiting the growth of cancer cells; reagents for medical purposes; anticancer agent; diagnostic reagents for medical purposes; pharmaceutical preparationstumor suppressors; cells for medical use; dietetic infusionssugarfoodsbeverage substances adapted for medical use; biological preparations for veterinary purposes for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer
Class 35
Online advertising on a computer network; advertising services; publicity agents; dissemination of advertising and advertising matter in the nature of flyersprospectusesbrochuresleaflets and samples; providing commercial information and advice for consumers in the choice of products and services; organization of exhibitions and trade fairs for commercial or advertising purposes; import-export agency services; marketing services; sponsorship search; retail store services for pharmaceuticalveterinary and sanitary preparations and medical supplies; wholesale store services for pharmaceuticalveterinary and sanitary preparations and medical supplies
Class 42
Research and development of new products for others; technological research in the field of chemical and biological medicaments; chemical analysis; biochemical research and analysis; research and development in the field of pharmaceutical preparations; medical research service; research and development services in the field of antibodies; stem cell research services; medical research; medical and scientific researchconducting clinical trials for others; biological research; computer programming in the field of medical aspects
Class 44
Preparation of prescriptions by pharmacists; stem cell therapy services; medical clinic services; providing medical information; DNA screening for medical purposes; medical analysis services for the diagnosis of cancer; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical screening; health care; medical assistance
Publications
History of USPTO decisions and trademark events.
29 publications found
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/22/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/22/2026
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/26/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/05/2026
FIMP
FINAL DISPOSITION PROCESSED
03/05/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/20/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/19/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
08/19/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/03/2025
PUBO
PUBLISHED FOR OPPOSITION
06/03/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/28/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/05/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
05/05/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/05/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
05/05/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/05/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/23/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/23/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/23/2025
RFNT
REFUSAL PROCESSED BY IB
03/29/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/12/2025
RFRR
REFUSAL PROCESSED BY MPU
03/12/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/03/2025
CNRT
NON-FINAL ACTION WRITTEN
02/02/2025
DOCK
ASSIGNED TO EXAMINER
01/30/2025
MAFR
APPLICATION FILING RECEIPT MAILED
01/29/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/29/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/23/2025
Continuous trademark protection
Get notified about every new filing that threatens ACELLYTRON THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.